Each line of mouse has different functional and nonfunctional cells, making each suited for different experiments. Some examples include SCID-hu Thy/Liv mice, which are given human fetal thymus and liver cells, hu-SRC-SCID mice, which are implanted with human hematopoietic stem cells (HSC), and hu-PBL-SCID mice, in which human peripheral blood mononuclear cells have been injected. There are many types of SCID mice used by researchers at present. Some SCID mice are shown to reject skin grafts, so it has been proposed that this disease arises from a leaky mutation, meaning that some mice with SCIDs do in fact have a somewhat functional adaptive immune system. This failure to create antibodies prevents most SCID mice from rejecting non-self tissues. The absence of functional B cells results in an organism that is unable to produce antibodies. Due to their immunodeficiency, mice with SCIDs often die young if not kept under extremely sterile conditions. Some SCID mice are able to produce monocytes, granulocytes, and red blood cells from the hematopoietic stem cells (HSC) present in their bone marrow. This results in a lack of B and T cells in the thymus and in the secondary lymphoid organs, such as the spleen and lymph nodes. Mice with SCIDs have lymphocyte progenitors, but these cells are unable to survive to maturity. This has implications for B and T cell receptor development, which is dependent upon such double-stranded breaks and subsequent repairs in order to rearrange V, D, J or V and J segments. SCIDs occurs in these mice due to a mutation in the gene for protein kinase, DNA activated, catalytic polypeptide (PRKDC), which plays a role in repairing double-stranded DNA breaks. The mutation causing SCIDs in mice was discovered by Melvin and Gayle Bosma in 1983 in the CB/17 mouse line. These mice allow researchers to study the human immune system and human disease in a small animal model. Human immune cells are used to develop human lymphoid organs within these immunodeficient mice, and many different types of SCID mouse models have been developed. Mice with severe combined immunodeficiency (SCIDs) are often used in the research of human disease. Therefore, xenotransplantation of human cells in NOD/SCID mice will provide a basis to further study the mechanisms of mobilization and the biology of the mobilized primitive human hematopoietic cell.Mice used in the research of human disease like AIDS 019) with a high or low dose of human G-CSF, alone or in combination with human stem-cell factor (SCF), with an average increase of 4.6-fold over control. Among the different mobilization regimens tested, human clonogenic cells could be mobilized from the BM into the PB (P =. Engraftment of human cells was detectable for up to 6.5 months after transplantation and, depending on the number of cells injected, reached as high as 96% in the bone marrow (BM), displaying an organ-specific maturation pattern of T- and B-lymphoid and myeloid cells. To study the mobilization of human progenitor cells in an experimental animal model in response to different treatment regimens, we injected intravenously a total of 92 immunodeficient nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with various numbers of granulocyte colony-stimulating factor (G-CSF) -mobilized CD34(+) PB cells (ranging from 2 to 50 x 10(6) cells per animal). However, the mechanisms involved in the mobilization of human hematopoietic stem and progenitor cells are largely unknown. Mobilized CD34(+) cells from human peripheral blood (PB) are increasingly used for hematopoietic stem-cell transplantation.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |